The design and synthesis of inhibitors of the cysteinyl protease, Der p I

Jeremy Billson(Peptide Protein Research (United Kingdom)), Richard Scott(Napp Pharmaceuticals (United Kingdom)), Martin Quibell(Napp Pharmaceuticals (United Kingdom)), Steven Langston(Millennium Engineering and Integration (United States)), Tony Johnson(University of Liverpool), Jonathan Clark(Napp Pharmaceuticals (United Kingdom)), T. W. HART(Napp Pharmaceuticals (United Kingdom)), Manoj K. Ramjee(Napp Pharmaceuticals (United Kingdom)), Simon P. Conway
Bioorganic & Medicinal Chemistry Letters
May 1, 1998
10.1016/s0960-894x(98)00151-6
Cited by 13

Related Papers

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
|Nature|2009|2k
Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
|Molecular Cell|2010|461
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment
|Nature Medicine|2018|453
MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-κB–dependent lymphoma
|Blood|2010|323
Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor
|Nature Chemical Biology|2017|228